Your Insurance Company, Your Pharmacy, and Your PBM Might All Be the Same Company

The letter arrived in March. Maria had been on a specialty biologic for her Crohn's disease for three years — stable, doing well, no hospitalizations. Her insurer denied the prior authorization renewal, citing insufficient clinical justification. She appealed. During the appeals process, she received a second letter: the denial was maintained, and she was directed to use a specific specialty pharmacy to continue receiving the medication, pending a new prior authorization approval from the same insurer.

Maria is a composite, but her situation is not unusual. What she discovered when she looked more carefully at the entities involved is that her insurer, the company that managed her pharmacy benefit, and the specialty pharmacy she was being directed to use all operated under the same corporate parent.

The three largest health insurance conglomerates — UnitedHealth Group, CVS Health, and Cigna — also own the three largest pharmacy benefit managers and extensive specialty pharmacy networks. When a drug is denied or a copay seems unexpectedly high, the decision often involves a company that simultaneously profits from your insurance coverage, manages your prescription benefit, and stands to dispense your drugs. That is not a conflict of interest in the legal sense. It is, however, the structure of the American drug distribution system in 2026.

The Vertical Integration Map

Understanding what happened to your prescription requires understanding who controls each step of its journey.

A pharmacy benefit manager, or PBM, is the intermediary between your insurance plan and the pharmacy that dispenses your drugs. PBMs negotiate drug prices with manufacturers, design formularies that determine which drugs are covered at which cost-sharing level, process claims, and manage the network of pharmacies you can use. They also operate their own pharmacies.

UnitedHealth Group owns OptumRx, one of the three largest PBMs in the United States, which processes hundreds of millions of prescription claims annually. Optum also operates a network of specialty pharmacies and infusion services. UnitedHealth Group's insurance operations, which include UnitedHealthcare, are among the largest in the country. The same parent company collects your insurance premium, manages your drug benefit, and can dispense your medication.

CVS Health operates differently but arrives at a similar structure. Its Caremark subsidiary is the largest PBM in the United States by claims volume, according to the Drug Channels Institute's 2026 Economic Report on U.S. Pharmacies and PBMs.¹ CVS Health also owns Aetna, one of the largest commercial and Medicare health insurers, as well as CVS Specialty and Coram infusion services. The company that insures you is the same company managing your pharmacy benefit and potentially dispensing your specialty drugs.

Cigna's structure runs through its Evernorth subsidiary, which owns Express Scripts, the second-largest PBM by claims volume. Cigna's health insurance operations cover tens of millions of people. Express Scripts manages formularies and pharmacy networks that include specialty pharmacy operations.

The Drug Channels Institute's 2026 vertical integration update documented the continued deepening of these corporate structures across insurer, PBM, and specialty pharmacy operations.¹

Why This Structure Matters for Your Drug Coverage

Formulary design is not neutral. When an insurer-affiliated PBM designs a formulary, it is making decisions about which drugs will be preferred, which will require prior authorization, and which will be covered only through specific pharmacies. When the company designing that formulary also operates specialty pharmacies that dispense those drugs, there is a financial incentive embedded in the coverage decision that has nothing to do with clinical appropriateness.

White-bagging is a policy that requires specialty drugs to be dispensed through the PBM-affiliated specialty pharmacy and shipped to the clinical setting, rather than purchased by the hospital or infusion center. This practice shifts the dispensing margin from the clinical site to the PBM-affiliated pharmacy. The Drug Channels Institute has documented that white-bagging policies have expanded significantly across major commercial and Medicare Advantage plans, with insurer-affiliated PBMs being the primary architects of those policies.¹

Site-of-care restrictions direct where you can receive infusion therapy, frequently steering patients toward the insurer's owned or affiliated infusion centers. In some cases, clinical sites not on the approved list cannot receive the drug through the plan's coverage at all. Physicians who recommend a specific infusion site based on a patient's clinical profile may find that the plan's coverage policies make that recommendation difficult to follow.

These practices are legal. They are also increasingly the subject of legislative and regulatory attention. The American Hospital Association and a number of state hospital associations have challenged white-bagging policies in court, with mixed results across jurisdictions.

What You Can Do

The first step is knowing which entities are affiliated with your insurer. Your plan's Summary of Benefits and your insurer's website should disclose which pharmacy benefit manager administers your drug benefit. A search of the corporate parent's subsidiaries — available in annual reports filed with the Securities and Exchange Commission — will show which specialty pharmacies and infusion services operate under the same company.

If you are being directed to a specific specialty pharmacy for a drug your physician administers in a clinical setting, ask your physician whether there is a clinical reason to use a different site. Site-of-care restrictions can often be appealed when there is a documented medical reason — the clinical site's capability, your clinical complexity, established care relationships, or a prior adverse event at the type of facility the plan prefers.

For specialty drugs dispensed through a pharmacy, most plans have a medical exception process for using a non-preferred specialty pharmacy when there is a clinical reason. Your physician would need to document that reason in writing. Examples that typically support such exceptions include the drug's storage or handling requirements, your clinical history with a specific pharmacist or pharmacy team, or a prior adverse event with a different dispensing method.

Prior authorization denials for specialty drugs can be appealed through the standard internal appeals process and, if that is unsuccessful, through external independent review. The external reviewer is independent of your insurer and its affiliates.

The Rebate Is Not the Price

One additional structural element that affects your out-of-pocket costs: the list price of a specialty drug is not the price the PBM negotiates with the manufacturer. PBMs negotiate rebates — payments from manufacturers in exchange for favorable formulary placement. Those rebates flow to the PBM, which may pass some portion to the plan sponsor but retains a portion as margin. Your cost-sharing at the pharmacy counter is often calculated based on the list price, not the net price after rebates.

This means your copay or coinsurance may be calculated on a price that nobody in the distribution chain actually paid. The structure exists because rebate flows are confidential and because the regulatory framework does not require net price transparency. CMS has proposed and implemented partial reforms to this structure in Medicare Part D, but commercial insurance remains largely unreformed.

The Complaint Window

If you believe a site-of-care restriction, white-bagging requirement, or formulary design caused you harm or prevented you from accessing a clinically appropriate drug, you can file a complaint with your state insurance department. State regulators have authority over commercial insurance plans (though not over self-funded employer plans, which are regulated federally under ERISA). Several states have enacted laws restricting or regulating white-bagging policies. Your state insurance department's website will list its current regulatory positions.

For Medicare Advantage plans, complaints about prior authorization denials or coverage restrictions can be filed with CMS's Medicare complaint system at medicare.gov or by calling 1-800-MEDICARE.

¹ Drug Channels Institute. "2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers." 2026.